| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 58 | 2026 | 874 | 8.090 |
Why?
|
| Antineoplastic Agents | 43 | 2025 | 686 | 6.240 |
Why?
|
| Molecular Targeted Therapy | 17 | 2024 | 137 | 3.760 |
Why?
|
| Precision Medicine | 14 | 2024 | 82 | 3.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2026 | 433 | 2.360 |
Why?
|
| Neoplastic Stem Cells | 10 | 2022 | 141 | 2.310 |
Why?
|
| Clinical Trials, Phase I as Topic | 8 | 2022 | 32 | 2.170 |
Why?
|
| Hedgehog Proteins | 12 | 2022 | 35 | 2.040 |
Why?
|
| Sulfonamides | 11 | 2025 | 73 | 1.820 |
Why?
|
| Medical Oncology | 6 | 2023 | 98 | 1.770 |
Why?
|
| Humans | 133 | 2026 | 28851 | 1.700 |
Why?
|
| National Cancer Institute (U.S.) | 18 | 2025 | 30 | 1.690 |
Why?
|
| Signal Transduction | 13 | 2025 | 1469 | 1.660 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 23 | 1.540 |
Why?
|
| Receptors, Notch | 6 | 2016 | 44 | 1.480 |
Why?
|
| Pyrazoles | 5 | 2026 | 79 | 1.470 |
Why?
|
| Middle Aged | 60 | 2026 | 7414 | 1.280 |
Why?
|
| Protein Kinase Inhibitors | 13 | 2026 | 165 | 1.260 |
Why?
|
| Aged | 50 | 2026 | 5598 | 1.230 |
Why?
|
| Female | 76 | 2026 | 15624 | 1.190 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2009 | 59 | 1.160 |
Why?
|
| Mutation | 20 | 2025 | 867 | 1.150 |
Why?
|
| Male | 70 | 2026 | 13921 | 1.140 |
Why?
|
| Pyridines | 12 | 2025 | 108 | 1.130 |
Why?
|
| Adult | 51 | 2026 | 8024 | 1.110 |
Why?
|
| Clinical Trials as Topic | 9 | 2019 | 218 | 1.100 |
Why?
|
| Pyrimidines | 11 | 2026 | 128 | 1.000 |
Why?
|
| United States | 18 | 2025 | 2222 | 1.000 |
Why?
|
| Aged, 80 and over | 23 | 2026 | 2065 | 0.980 |
Why?
|
| Pyrimidinones | 3 | 2024 | 16 | 0.960 |
Why?
|
| Enzyme Inhibitors | 4 | 2021 | 251 | 0.930 |
Why?
|
| Anilides | 10 | 2025 | 24 | 0.930 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2024 | 97 | 0.930 |
Why?
|
| Cell Cycle Proteins | 4 | 2024 | 187 | 0.880 |
Why?
|
| Lung Neoplasms | 10 | 2024 | 360 | 0.870 |
Why?
|
| Biomarkers, Tumor | 10 | 2024 | 415 | 0.850 |
Why?
|
| Multiple Myeloma | 6 | 2006 | 39 | 0.850 |
Why?
|
| Maximum Tolerated Dose | 15 | 2026 | 34 | 0.840 |
Why?
|
| Hydroxamic Acids | 2 | 2024 | 22 | 0.830 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 44 | 0.830 |
Why?
|
| Tumor Microenvironment | 5 | 2024 | 194 | 0.800 |
Why?
|
| Treatment Outcome | 26 | 2026 | 2426 | 0.760 |
Why?
|
| Aniline Compounds | 5 | 2025 | 23 | 0.750 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2019 | 67 | 0.720 |
Why?
|
| Esophageal Neoplasms | 2 | 2024 | 33 | 0.710 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 44 | 0.700 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 7 | 2004 | 29 | 0.690 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2020 | 26 | 0.660 |
Why?
|
| Drug Design | 3 | 2015 | 63 | 0.660 |
Why?
|
| Apoptosis | 7 | 2025 | 780 | 0.650 |
Why?
|
| Liver Diseases | 2 | 2024 | 52 | 0.650 |
Why?
|
| Patient Selection | 4 | 2017 | 150 | 0.640 |
Why?
|
| Methotrexate | 6 | 2003 | 36 | 0.630 |
Why?
|
| Immune System | 1 | 2019 | 29 | 0.630 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2021 | 170 | 0.620 |
Why?
|
| Peripheral Nervous System | 1 | 2019 | 2 | 0.610 |
Why?
|
| Cytotoxins | 2 | 2019 | 51 | 0.610 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2019 | 120 | 0.610 |
Why?
|
| Long Term Adverse Effects | 1 | 2019 | 2 | 0.610 |
Why?
|
| Immunologic Factors | 2 | 2019 | 50 | 0.610 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2019 | 30 | 0.610 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2019 | 14 | 0.610 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 18 | 0.610 |
Why?
|
| Genetic Therapy | 5 | 2015 | 124 | 0.600 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 33 | 0.600 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2024 | 105 | 0.600 |
Why?
|
| Genomics | 6 | 2024 | 124 | 0.590 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2017 | 48 | 0.590 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2016 | 33 | 0.590 |
Why?
|
| Indoles | 8 | 2025 | 110 | 0.550 |
Why?
|
| Genetic Testing | 2 | 2017 | 68 | 0.540 |
Why?
|
| Young Adult | 17 | 2025 | 2833 | 0.540 |
Why?
|
| Glioblastoma | 3 | 2024 | 109 | 0.530 |
Why?
|
| Wnt Signaling Pathway | 2 | 2015 | 67 | 0.520 |
Why?
|
| Cisplatin | 6 | 2025 | 186 | 0.520 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2025 | 16 | 0.510 |
Why?
|
| Brain Neoplasms | 4 | 2024 | 312 | 0.510 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2016 | 20 | 0.510 |
Why?
|
| Research Design | 5 | 2016 | 187 | 0.510 |
Why?
|
| Piperazines | 3 | 2024 | 50 | 0.510 |
Why?
|
| Biomarkers | 5 | 2016 | 776 | 0.500 |
Why?
|
| Mycophenolic Acid | 3 | 2015 | 18 | 0.500 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 25 | 0.500 |
Why?
|
| Retroviridae | 8 | 2004 | 16 | 0.490 |
Why?
|
| Liver | 1 | 2019 | 471 | 0.490 |
Why?
|
| Gallbladder Neoplasms | 1 | 2016 | 14 | 0.480 |
Why?
|
| Genetic Research | 1 | 2015 | 6 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 347 | 0.470 |
Why?
|
| IMP Dehydrogenase | 2 | 2006 | 4 | 0.470 |
Why?
|
| Genetic Markers | 1 | 2015 | 92 | 0.470 |
Why?
|
| High-Throughput Nucleotide Sequencing | 8 | 2023 | 118 | 0.470 |
Why?
|
| Glioma | 3 | 2022 | 122 | 0.450 |
Why?
|
| Adrenocortical Carcinoma | 2 | 2024 | 5 | 0.430 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2024 | 6 | 0.430 |
Why?
|
| Neoplasm Metastasis | 5 | 2014 | 164 | 0.420 |
Why?
|
| Benzimidazoles | 2 | 2025 | 32 | 0.410 |
Why?
|
| Dipeptides | 3 | 2021 | 22 | 0.410 |
Why?
|
| Sarcoma, Alveolar Soft Part | 2 | 2023 | 3 | 0.410 |
Why?
|
| Child | 14 | 2025 | 2287 | 0.400 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 465 | 0.400 |
Why?
|
| Wnt Proteins | 2 | 2010 | 43 | 0.390 |
Why?
|
| Drug Discovery | 2 | 2012 | 37 | 0.390 |
Why?
|
| Cell Line, Tumor | 12 | 2025 | 1350 | 0.390 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 224 | 0.390 |
Why?
|
| Child, Preschool | 10 | 2025 | 1173 | 0.390 |
Why?
|
| Antigens, CD34 | 5 | 2009 | 14 | 0.380 |
Why?
|
| Drug Delivery Systems | 2 | 2017 | 236 | 0.380 |
Why?
|
| Sulfides | 2 | 2024 | 40 | 0.380 |
Why?
|
| Ipilimumab | 2 | 2025 | 4 | 0.370 |
Why?
|
| Animals | 24 | 2024 | 10684 | 0.360 |
Why?
|
| Adolescent | 14 | 2025 | 3193 | 0.360 |
Why?
|
| Sarcoma | 2 | 2022 | 29 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2025 | 612 | 0.350 |
Why?
|
| Drug Resistance | 3 | 2003 | 42 | 0.350 |
Why?
|
| Dasatinib | 6 | 2016 | 18 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2016 | 12 | 0.340 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2024 | 14 | 0.340 |
Why?
|
| Mice | 17 | 2024 | 4802 | 0.330 |
Why?
|
| Cell Proliferation | 4 | 2024 | 824 | 0.320 |
Why?
|
| Prognosis | 5 | 2024 | 811 | 0.320 |
Why?
|
| Combined Modality Therapy | 7 | 2016 | 303 | 0.320 |
Why?
|
| Blood Specimen Collection | 1 | 2009 | 14 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2025 | 68 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2015 | 84 | 0.300 |
Why?
|
| Fetal Blood | 1 | 2009 | 40 | 0.300 |
Why?
|
| Placenta | 1 | 2009 | 78 | 0.290 |
Why?
|
| Germ-Line Mutation | 2 | 2025 | 31 | 0.290 |
Why?
|
| DNA, Complementary | 4 | 2001 | 78 | 0.290 |
Why?
|
| Nuclear Proteins | 4 | 2024 | 249 | 0.290 |
Why?
|
| 3T3 Cells | 6 | 2003 | 46 | 0.280 |
Why?
|
| Gene Transfer Techniques | 8 | 2008 | 74 | 0.280 |
Why?
|
| Disease Progression | 6 | 2020 | 477 | 0.270 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2024 | 62 | 0.270 |
Why?
|
| Drugs, Investigational | 2 | 2022 | 5 | 0.270 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2025 | 38 | 0.270 |
Why?
|
| Drug Synergism | 3 | 2024 | 106 | 0.270 |
Why?
|
| Neoplasm Staging | 6 | 2019 | 480 | 0.270 |
Why?
|
| Biopsy | 5 | 2020 | 208 | 0.270 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2024 | 52 | 0.270 |
Why?
|
| Smoothened Receptor | 2 | 2025 | 9 | 0.260 |
Why?
|
| Endothelial Cells | 2 | 2008 | 373 | 0.260 |
Why?
|
| Immunosuppressive Agents | 3 | 2006 | 150 | 0.260 |
Why?
|
| Melanoma | 2 | 2023 | 140 | 0.260 |
Why?
|
| Cyclophosphamide | 4 | 2006 | 43 | 0.250 |
Why?
|
| Pyrroles | 4 | 2024 | 36 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2026 | 13 | 0.250 |
Why?
|
| Gene Amplification | 1 | 2026 | 23 | 0.250 |
Why?
|
| Exons | 1 | 2026 | 43 | 0.250 |
Why?
|
| Incidence | 2 | 2019 | 572 | 0.250 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2024 | 36 | 0.240 |
Why?
|
| Infant | 6 | 2025 | 1025 | 0.240 |
Why?
|
| Interleukin-15 | 1 | 2025 | 2 | 0.240 |
Why?
|
| Caspases | 1 | 2006 | 43 | 0.240 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2024 | 79 | 0.240 |
Why?
|
| Patched-1 Receptor | 1 | 2025 | 4 | 0.240 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2025 | 30 | 0.240 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 482 | 0.240 |
Why?
|
| Kidney Neoplasms | 2 | 2024 | 103 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 3 | 2017 | 548 | 0.230 |
Why?
|
| Genetic Vectors | 8 | 2008 | 118 | 0.230 |
Why?
|
| DNA Repair | 2 | 2024 | 82 | 0.230 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2005 | 2 | 0.230 |
Why?
|
| Ascites | 1 | 2005 | 19 | 0.230 |
Why?
|
| Ubiquitin-Activating Enzymes | 2 | 2024 | 4 | 0.230 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2025 | 5 | 0.230 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2025 | 16 | 0.230 |
Why?
|
| Neurofibromin 2 | 1 | 2024 | 3 | 0.230 |
Why?
|
| Fluorouracil | 3 | 2017 | 58 | 0.230 |
Why?
|
| Spheroids, Cellular | 1 | 2025 | 53 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2024 | 4 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2024 | 9 | 0.220 |
Why?
|
| Disease-Free Survival | 10 | 2016 | 236 | 0.220 |
Why?
|
| TRPM Cation Channels | 1 | 2024 | 9 | 0.220 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2024 | 6 | 0.220 |
Why?
|
| Benzamides | 5 | 2025 | 39 | 0.220 |
Why?
|
| Leukemia | 3 | 2015 | 30 | 0.220 |
Why?
|
| Medulloblastoma | 2 | 2015 | 20 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 151 | 0.220 |
Why?
|
| Thiazoles | 4 | 2014 | 50 | 0.220 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2024 | 33 | 0.220 |
Why?
|
| Deoxycytidine | 5 | 2017 | 67 | 0.220 |
Why?
|
| bcl-X Protein | 1 | 2024 | 35 | 0.210 |
Why?
|
| Phthalazines | 1 | 2024 | 25 | 0.210 |
Why?
|
| Pyridones | 1 | 2024 | 36 | 0.210 |
Why?
|
| Metabolic Clearance Rate | 2 | 2024 | 18 | 0.210 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 82 | 0.210 |
Why?
|
| Bone Marrow | 2 | 2004 | 83 | 0.210 |
Why?
|
| Research Personnel | 2 | 2015 | 40 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 676 | 0.210 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 9 | 0.210 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2021 | 13 | 0.210 |
Why?
|
| Survival Analysis | 5 | 2020 | 288 | 0.210 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 38 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 42 | 0.200 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 607 | 0.200 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2004 | 233 | 0.190 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 137 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 133 | 0.190 |
Why?
|
| Risk Factors | 2 | 2019 | 2126 | 0.190 |
Why?
|
| Tamoxifen | 1 | 2022 | 34 | 0.190 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 167 | 0.180 |
Why?
|
| Infusions, Intravenous | 3 | 2019 | 102 | 0.180 |
Why?
|
| Platinum Compounds | 2 | 2019 | 14 | 0.180 |
Why?
|
| Gossypol | 2 | 2019 | 2 | 0.180 |
Why?
|
| src-Family Kinases | 3 | 2017 | 71 | 0.180 |
Why?
|
| Oxidoreductases | 1 | 2001 | 57 | 0.180 |
Why?
|
| DNA Damage | 4 | 2026 | 152 | 0.180 |
Why?
|
| Drug Approval | 2 | 2012 | 12 | 0.180 |
Why?
|
| Radiation Tolerance | 1 | 2021 | 28 | 0.170 |
Why?
|
| Prospective Studies | 2 | 2024 | 1280 | 0.170 |
Why?
|
| Ubiquitination | 1 | 2021 | 33 | 0.170 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2001 | 8 | 0.170 |
Why?
|
| Benzazepines | 2 | 2022 | 12 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 2 | 2011 | 15 | 0.170 |
Why?
|
| Thalidomide | 2 | 2019 | 14 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 465 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 179 | 0.170 |
Why?
|
| Moloney murine leukemia virus | 1 | 2000 | 1 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 82 | 0.160 |
Why?
|
| Blotting, Western | 6 | 2015 | 515 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2024 | 275 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 3 | 2018 | 336 | 0.160 |
Why?
|
| Hodgkin Disease | 3 | 2004 | 11 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2020 | 245 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 93 | 0.150 |
Why?
|
| Tubulin Modulators | 1 | 2019 | 17 | 0.150 |
Why?
|
| Proteasome Inhibitors | 1 | 2019 | 26 | 0.150 |
Why?
|
| Skin Neoplasms | 2 | 2011 | 147 | 0.150 |
Why?
|
| Models, Biological | 3 | 2024 | 469 | 0.150 |
Why?
|
| Transcriptome | 1 | 2021 | 231 | 0.150 |
Why?
|
| Pyrazines | 3 | 2025 | 25 | 0.150 |
Why?
|
| Carboplatin | 1 | 2019 | 121 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 74 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2015 | 33 | 0.150 |
Why?
|
| DNA, Neoplasm | 2 | 2015 | 34 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 91 | 0.140 |
Why?
|
| Thymidylate Synthase | 3 | 2004 | 7 | 0.140 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2009 | 10 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 108 | 0.140 |
Why?
|
| Paclitaxel | 1 | 2019 | 200 | 0.140 |
Why?
|
| Transduction, Genetic | 4 | 2003 | 28 | 0.140 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1998 | 12 | 0.140 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 22 | 0.140 |
Why?
|
| Etoposide | 5 | 2016 | 19 | 0.140 |
Why?
|
| Research Support as Topic | 2 | 2015 | 7 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 104 | 0.140 |
Why?
|
| HIV-1 | 1 | 1998 | 58 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2019 | 268 | 0.140 |
Why?
|
| Flow Cytometry | 3 | 2014 | 292 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2021 | 120 | 0.140 |
Why?
|
| Imatinib Mesylate | 2 | 2015 | 15 | 0.140 |
Why?
|
| Prevalence | 1 | 2019 | 518 | 0.130 |
Why?
|
| Clinical Laboratory Services | 1 | 2017 | 2 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2017 | 31 | 0.130 |
Why?
|
| Quality Control | 1 | 2017 | 21 | 0.130 |
Why?
|
| Intersectoral Collaboration | 1 | 2017 | 7 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 302 | 0.130 |
Why?
|
| Time Factors | 5 | 2012 | 1613 | 0.130 |
Why?
|
| Pentosyltransferases | 2 | 2012 | 7 | 0.130 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 11 | 0.130 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2016 | 12 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2019 | 631 | 0.130 |
Why?
|
| Esophagogastric Junction | 1 | 2016 | 6 | 0.130 |
Why?
|
| Radiobiology | 1 | 2016 | 5 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 2 | 2016 | 148 | 0.120 |
Why?
|
| Melphalan | 3 | 2006 | 7 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 429 | 0.120 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2015 | 9 | 0.120 |
Why?
|
| Computational Biology | 1 | 2017 | 156 | 0.120 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 15 | 0.120 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2015 | 20 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 524 | 0.120 |
Why?
|
| ErbB Receptors | 4 | 2020 | 100 | 0.120 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2015 | 41 | 0.120 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2015 | 22 | 0.120 |
Why?
|
| Japan | 2 | 2012 | 23 | 0.120 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2006 | 3 | 0.120 |
Why?
|
| Morpholines | 2 | 2025 | 28 | 0.110 |
Why?
|
| Fasciitis | 1 | 2015 | 4 | 0.110 |
Why?
|
| Bone Marrow Cells | 5 | 2004 | 81 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 72 | 0.110 |
Why?
|
| AC133 Antigen | 2 | 2018 | 7 | 0.110 |
Why?
|
| Receptor, Notch1 | 1 | 2015 | 27 | 0.110 |
Why?
|
| Phosphorylation | 3 | 2021 | 585 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 32 | 0.110 |
Why?
|
| Skin Diseases | 1 | 2015 | 30 | 0.110 |
Why?
|
| Salvage Therapy | 2 | 2004 | 37 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 2 | 0.110 |
Why?
|
| Calcineurin Inhibitors | 1 | 2014 | 5 | 0.110 |
Why?
|
| Amifostine | 2 | 2004 | 5 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2008 | 1022 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 18 | 0.110 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2014 | 11 | 0.110 |
Why?
|
| Recurrence | 5 | 2015 | 326 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2021 | 2635 | 0.100 |
Why?
|
| Chondrosarcoma | 1 | 2013 | 6 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 82 | 0.100 |
Why?
|
| Cerebellar Neoplasms | 1 | 2013 | 30 | 0.100 |
Why?
|
| Food-Drug Interactions | 1 | 2013 | 3 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2004 | 27 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2024 | 88 | 0.100 |
Why?
|
| Policy | 1 | 2012 | 13 | 0.100 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2012 | 3 | 0.090 |
Why?
|
| Guanidines | 1 | 2012 | 6 | 0.090 |
Why?
|
| Cyanides | 1 | 2012 | 4 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 4 | 2021 | 314 | 0.090 |
Why?
|
| DNA Primers | 3 | 2002 | 147 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 472 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 300 | 0.090 |
Why?
|
| Genes, Viral | 2 | 2002 | 10 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 140 | 0.090 |
Why?
|
| Transfection | 2 | 2002 | 319 | 0.090 |
Why?
|
| Hydroxychloroquine | 1 | 2011 | 20 | 0.090 |
Why?
|
| Peptides | 2 | 2014 | 296 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2005 | 328 | 0.080 |
Why?
|
| Administration, Intravenous | 2 | 2023 | 30 | 0.080 |
Why?
|
| Hair Follicle | 1 | 2010 | 10 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2002 | 270 | 0.080 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2010 | 15 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 79 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 292 | 0.080 |
Why?
|
| Autophagy | 1 | 2011 | 77 | 0.080 |
Why?
|
| Investigational New Drug Application | 1 | 2010 | 1 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 11 | 0.080 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 2 | 2017 | 9 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2021 | 222 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 93 | 0.080 |
Why?
|
| Phenotype | 3 | 2018 | 685 | 0.080 |
Why?
|
| Quinazolines | 2 | 2023 | 32 | 0.080 |
Why?
|
| Genital Neoplasms, Female | 1 | 2009 | 67 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 165 | 0.070 |
Why?
|
| Thymidine Kinase | 2 | 2000 | 6 | 0.070 |
Why?
|
| Coculture Techniques | 2 | 2007 | 55 | 0.070 |
Why?
|
| Transplantation Conditioning | 2 | 2006 | 13 | 0.070 |
Why?
|
| Immunotherapy | 3 | 2023 | 163 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2009 | 140 | 0.070 |
Why?
|
| Receptors, Virus | 1 | 2008 | 6 | 0.070 |
Why?
|
| Avian Proteins | 1 | 2008 | 5 | 0.070 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2008 | 5 | 0.070 |
Why?
|
| Hemangioma | 1 | 2008 | 8 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2009 | 124 | 0.070 |
Why?
|
| Prodrugs | 2 | 2017 | 30 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 53 | 0.070 |
Why?
|
| Caspase 3 | 2 | 2019 | 58 | 0.070 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2007 | 2 | 0.070 |
Why?
|
| Wnt3 Protein | 1 | 2007 | 3 | 0.070 |
Why?
|
| Transplantation, Autologous | 5 | 2006 | 42 | 0.070 |
Why?
|
| Mice, SCID | 1 | 2007 | 60 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2025 | 103 | 0.070 |
Why?
|
| Ribonucleotide Reductases | 1 | 2007 | 1 | 0.070 |
Why?
|
| Thiosemicarbazones | 1 | 2007 | 5 | 0.070 |
Why?
|
| beta Catenin | 1 | 2007 | 66 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2007 | 139 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 67 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2021 | 267 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 463 | 0.060 |
Why?
|
| Guanosine | 1 | 2006 | 5 | 0.060 |
Why?
|
| Receptor, trkC | 1 | 2026 | 3 | 0.060 |
Why?
|
| Bortezomib | 1 | 2026 | 23 | 0.060 |
Why?
|
| Receptor, trkA | 1 | 2026 | 11 | 0.060 |
Why?
|
| Colony-Forming Units Assay | 2 | 2004 | 8 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 29 | 0.060 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2026 | 25 | 0.060 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 15 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2025 | 8 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 97 | 0.060 |
Why?
|
| Imidazoles | 1 | 2025 | 63 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2006 | 163 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2019 | 897 | 0.060 |
Why?
|
| Mitochondrial Proteins | 2 | 2015 | 80 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2005 | 67 | 0.060 |
Why?
|
| Plasmacytoma | 1 | 2004 | 5 | 0.060 |
Why?
|
| Guanosine Triphosphate | 1 | 2004 | 29 | 0.060 |
Why?
|
| Guanine | 1 | 2004 | 25 | 0.060 |
Why?
|
| Cytoprotection | 1 | 2004 | 24 | 0.060 |
Why?
|
| Glutamates | 1 | 2004 | 14 | 0.060 |
Why?
|
| Pregnancy | 1 | 2009 | 1254 | 0.060 |
Why?
|
| Cyclin D | 1 | 2024 | 2 | 0.060 |
Why?
|
| Hydroxylamines | 1 | 2024 | 6 | 0.060 |
Why?
|
| Piperidines | 1 | 2025 | 48 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2004 | 5 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2024 | 8 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2024 | 49 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 20 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2024 | 19 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 131 | 0.050 |
Why?
|
| Mitotane | 1 | 2024 | 1 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 334 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 25 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2004 | 22 | 0.050 |
Why?
|
| Radiation-Protective Agents | 1 | 2004 | 22 | 0.050 |
Why?
|
| Organoids | 1 | 2024 | 23 | 0.050 |
Why?
|
| Heterografts | 1 | 2024 | 66 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2017 | 190 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2002 | 19 | 0.050 |
Why?
|
| SMARCB1 Protein | 1 | 2023 | 5 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 14 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 135 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 95 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 5 | 2014 | 1653 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2023 | 35 | 0.050 |
Why?
|
| Blotting, Northern | 2 | 2000 | 46 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 54 | 0.050 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cyclin E | 1 | 2022 | 3 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2015 | 110 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 285 | 0.050 |
Why?
|
| Ganciclovir | 2 | 2000 | 7 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Body Weight | 1 | 2023 | 250 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 102 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 513 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1032 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 344 | 0.050 |
Why?
|
| Fluorocarbons | 1 | 2022 | 6 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 26 | 0.050 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 25 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 26 | 0.050 |
Why?
|
| Time | 1 | 2002 | 16 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2022 | 46 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 101 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2000 | 114 | 0.040 |
Why?
|
| Brain | 1 | 2007 | 769 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 634 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 117 | 0.040 |
Why?
|
| Acrylamides | 1 | 2020 | 5 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2021 | 39 | 0.040 |
Why?
|
| Dexamethasone | 3 | 2006 | 63 | 0.040 |
Why?
|
| Topotecan | 2 | 2011 | 12 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 490 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 49 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2001 | 126 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 58 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 137 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 2000 | 27 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2023 | 916 | 0.040 |
Why?
|
| RNA | 1 | 2001 | 111 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2000 | 20 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 251 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2023 | 523 | 0.040 |
Why?
|
| Rituximab | 2 | 2015 | 64 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 94 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 148 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2018 | 26 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2018 | 6 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2018 | 20 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 13 | 0.040 |
Why?
|
| Purines | 1 | 1998 | 17 | 0.040 |
Why?
|
| Cytokines | 2 | 2010 | 451 | 0.040 |
Why?
|
| Solubility | 1 | 1998 | 73 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 2000 | 189 | 0.040 |
Why?
|
| CA-19-9 Antigen | 1 | 2017 | 7 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 22 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1997 | 5 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 416 | 0.030 |
Why?
|
| NIH 3T3 Cells | 2 | 2008 | 44 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 26 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2015 | 8 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 15 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 50 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 15 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 73 | 0.030 |
Why?
|
| Immunoassay | 1 | 2015 | 36 | 0.030 |
Why?
|
| Vidarabine | 1 | 2015 | 3 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2015 | 30 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 13 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 37 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 65 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2015 | 6 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 72 | 0.030 |
Why?
|
| Joints | 1 | 2015 | 12 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 194 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 237 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 48 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 54 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 63 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 332 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2014 | 23 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 8 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2014 | 27 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2014 | 31 | 0.030 |
Why?
|
| Taxoids | 1 | 2014 | 37 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2014 | 10 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 285 | 0.030 |
Why?
|
| France | 1 | 2013 | 15 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 21 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 465 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 285 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2014 | 78 | 0.030 |
Why?
|
| Cytostatic Agents | 1 | 2012 | 2 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 35 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 87 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 376 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 41 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 485 | 0.020 |
Why?
|
| NADP | 1 | 2012 | 39 | 0.020 |
Why?
|
| Superoxides | 1 | 2012 | 62 | 0.020 |
Why?
|
| Niacinamide | 1 | 2012 | 32 | 0.020 |
Why?
|
| Glutathione | 1 | 2012 | 76 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 396 | 0.020 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2011 | 2 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 22 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 50 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 380 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2010 | 13 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2011 | 52 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2011 | 80 | 0.020 |
Why?
|
| ras Proteins | 1 | 2010 | 43 | 0.020 |
Why?
|
| Mesylates | 1 | 2010 | 3 | 0.020 |
Why?
|
| Texas | 1 | 2010 | 138 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 113 | 0.020 |
Why?
|
| Financing, Government | 1 | 2009 | 7 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 100 | 0.020 |
Why?
|
| Gene Expression | 2 | 2003 | 417 | 0.020 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Oncogenes | 1 | 2008 | 34 | 0.020 |
Why?
|
| Chickens | 1 | 2008 | 62 | 0.020 |
Why?
|
| Transgenes | 1 | 2008 | 63 | 0.020 |
Why?
|
| Models, Animal | 1 | 2008 | 130 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 481 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 1988 | 90 | 0.020 |
Why?
|
| HeLa Cells | 1 | 1988 | 212 | 0.020 |
Why?
|
| Stem Cells | 1 | 2008 | 123 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 1507 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1988 | 404 | 0.020 |
Why?
|
| DNA | 1 | 1988 | 377 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2006 | 1 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 667 | 0.020 |
Why?
|
| Thionucleotides | 1 | 2005 | 5 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 22 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 18 | 0.010 |
Why?
|
| Pemetrexed | 1 | 2004 | 7 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2004 | 34 | 0.010 |
Why?
|
| Leukapheresis | 1 | 2004 | 3 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2004 | 46 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 18 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 553 | 0.010 |
Why?
|
| Sulfites | 1 | 2003 | 8 | 0.010 |
Why?
|
| Methylation | 1 | 2003 | 24 | 0.010 |
Why?
|
| Base Sequence | 2 | 1998 | 588 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 111 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 226 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 42 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 419 | 0.010 |
Why?
|
| Thioguanine | 1 | 1998 | 1 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2000 | 668 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1988 | 122 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1988 | 697 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1988 | 1056 | 0.000 |
Why?
|